HIV PrEP: biology + behaviour + chemistry

In this episode, we dive into the essential updates from the ASHM 2025 National PrEP Guidelines, providing a comprehensive clinical management and prescribing summary tailored for GPs and Nurse Practitioners.

Join us as we break down exactly how Pre-Exposure Prophylaxis (PrEP) works, utilizing co-formulated tenofovir disoproxil and emtricitabine (TD/FTC) to safely block HIV replication before an infection can establish. Whether you are looking to refresh your day-to-day clinical prescribing knowledge or hunting for high-yield exam pearls for the AKT or KFP, this episode covers all the practical steps you need to know.

Key topics covered in this episode:

• Patient Suitability & Clinical Assessment: Discover who is most at risk and the critical pre-screening steps required before prescribing. We cover why you must always use a 4th-generation venous HIV Ag/Ab test, the importance of excluding acute HIV, and how to properly check renal function (eGFR).
• Daily vs. On-Demand (2-1-1) Dosing: We explore the critical differences between continuous daily PrEP and the off-label, event-driven "2-1-1" method. You will learn the strict eligibility criteria for on-demand use and the necessary timelines to achieve protective drug levels.
• Contraindications & Specialist Referrals: Learn when PrEP is absolutely contraindicated (such as untreated acute HIV or an eGFR < 30) and the specific scenarios where a patient should be promptly referred to a specialist or an s100 HIV prescriber.
• Patient Counselling & Ongoing Monitoring: Get practical tips on communicating the importance of adherence, managing "start-up syndrome" side effects, conducting mandatory quarterly STI and HIV testing, and the specific rules for safely stopping PrEP based on the patient's biological sex and hormone use.

Tune in to ensure your HIV prevention and prescribing practices are up-to-date, safe, and highly effective for your patients!

Transcript

SPEAKER_01 0:00

You know, usually uh the whole concept of taking medication is inherently reactive. Like you get a headache, you take a painkiller, you catch a bacterial infection, you take an antibiotic. Right. The entire premise of modern medicine, for the most part anyway, is that something in your body is already broken or under attack, I guess. And the pill is there to fix it.

SPEAKER_00 0:20

Aaron Powell It is fundamentally a system of troubleshooting. I mean, you wait for the alarm to go off and then you send in the fire trucks.

SPEAKER_01 0:27

Exactly.

SPEAKER_00 0:28

And by that point, you're already managing damage.

SPEAKER_01 0:30

Aaron Powell But what if you could take a pill when you are perfectly healthy? And by doing so, you essentially build like an invisible biological shield.

SPEAKER_00 0:39

Aaron Powell Which is pretty wild to think about.

SPEAKER_01 0:40

Aaron Powell A shield so effective that a virus that once completely redefined global public health just well, bounces off. That is the reality we are looking at today. So welcome to this deep dive.

SPEAKER_00 0:52

Glad to be here.

SPEAKER_01 0:52

Trevor Burrus Today we're opening up a pretty dense, highly specific medical roadmap. We've got the ASHM National Pre-AP Guidelines 2025 alongside the ASHM Pre-P tool.

SPEAKER_00 1:03

And these documents represent far more than just, you know, a basic summary of a drug. They're basically a masterclass in modern preventative medicine.

SPEAKER_01 1:12

Aaron Powell Yeah, they really show how doctors actually navigate human behavior, biology, and risk, right? Aaron Powell Absolut Aaron Aaron Ross Powell. So our mission today is to decode this clinical guidance for you. We are going to figure out exactly how HIV pre-exposure prophylaxis, which we'll just call P-R-E-P from here on out, actually works inside the human body.

SPEAKER_00 1:31

Aaron Powell Because it's not just magic, right? There are real mechanics at play here.

SPEAKER_01 1:35

Aaron Powell We'll look at who it's for and the incredibly fascinating biological mechanics of how different bodies process this drug. Because as you're about to see, this isn't just about swallowing a pill with your morning coffee.

SPEAKER_00 1:46

Far from it.

SPEAKER_01 1:47

It involves strategic math, biological timing, and a massive foundational shift in how the medical field views human behavioral risk. Okay, let's unpack this. Before we can talk about who gets this medication, we really need to understand what it is. Like what is this shield?

SPEAKER_00 2:03

Well, to understand the shield, we have to look at the specific tools building it. The core medication license for pre-IP in Australia is um it's a single coformulated pill.

SPEAKER_01 2:12

Aaron Powell Meaning two drugs in one, right?

SPEAKER_00 2:15

Exactly. It contains Tenefavir disapproxyl and intrisitabine. In the clinical world, you'll see this abbreviated as TDFTC.

SPEAKER_01 2:22

TDFTC. No, got it.

SPEAKER_00 2:24

Yeah. And these belong to a class of drugs called NRTIs, or nucleoside reverse transcriptase inhibitors.

SPEAKER_01 2:31

Okay, that is a massive mouthful, but essentially this is taken by someone who is strictly HIV negative, right? Like that's the baseline.

SPEAKER_00 2:38

Yes, exclusively HIV-negative individuals. Right. When you take this pill, those two drugs get absorbed and achieve what we call protective intracellular drug levels. They embed themselves right in the mucosal tissues.

SPEAKER_01 2:50

I love trying to visualize this. It's essentially like um installing a biological bouncer at a club's door. The club is your body.

SPEAKER_00 2:57

I like that analogy.

SPEAKER_01 2:58

The virus might manage to get inside the bl like into the mucosal tissue, but the bouncers are standing right at the edge of the dance floor waiting.

SPEAKER_00 3:05

That analogy actually maps perfectly to the biology. If an exposure occurs, the HIV virus enters the body and attempts to perform a process called reverse transcription.

SPEAKER_01 3:16

Which is how it copies itself.

SPEAKER_00 3:17

Right. It has to copy its viral RNA into DNA to hijack your body's cells and you know make itself a permanent resident.

SPEAKER_01 3:25

Yeah.

SPEAKER_00 3:25

But those bouncers, the NRTIs, are already waiting in the tissue.

SPEAKER_01 3:29

So they just block it.

SPEAKER_00 3:30

They structurally block that reverse transcription process. The replication is stopped cold before the infection can even establish a foothold. The virus is neutralized before the party even starts.

SPEAKER_01 3:41

Wow. So the chemical shield is incredibly robust. But looking at the guidelines, there's a fascinating secondary concept that determines whether the virus even poses a threat before it hits the bouncer. Ah, yes. It completely reframes conversation around transmission. It's the concept of you equals you.

SPEAKER_00 3:58

Undetectable equals untransmittable. The guidelines make this explicitly clear because, well, it changes the entire landscape of risk. If a partner is living with HLV, but they're on effective antiretroviral treatment and have an undetectable viral load, they pose absolutely zero risk of sexual transmission. None.

SPEAKER_01 4:17

That is such a monumentally important public health fact. I feel like not enough people realize that.

SPEAKER_00 4:22

It really changes everything. Pre-EP, therefore, is a tool for when a partner's status is unknown or when a partner living with HIV is not on effective treatment.

SPEAKER_01 4:31

It puts the power of prevention entirely in the hands of the HIV-negative person.

SPEAKER_00 4:35

Aaron Powell Exactly. But how well that shield works is dictated by a really crucial biological quirk.

SPEAKER_01 4:41

And this is where anatomy completely drives the medical strategy.

SPEAKER_00 4:45

Rectal tissue absorbs this specific drug to protective levels much, much faster than vaginal or cervical tissue does. Really? Yeah. That one microscopic biological fact is the underlying reason for all the complex dosing rules and timelines we'll get into later.

SPEAKER_01 4:59

It's incredible how a microscopic absorption rate dictates entire public health policies. Because the medication interacts dynamically with different bodies and behaviors, the medical guidelines have fundamentally changed how they classify who needs the shield in the first place. Right. Which brings us to how doctors actually evaluate risk today.

SPEAKER_00 5:18

If we connect this to the bigger picture, the medical field has completely overhauled how it evaluates human behavior. Up until about 2021, the ASHM guidelines classified risk into strict, almost rigid categories of like high risk or low risk.

SPEAKER_01 5:35

Which sounds like they were treating behavior as an identity rather than just an event.

SPEAKER_00 5:39

That was the exact problem. Categorizing people created stigma, and more importantly, it was clinically inaccurate. Risk is fluid, you know.

SPEAKER_01 5:46

Right.

SPEAKER_00 5:47

So they scrapped those rigid labels. Now doctors use a dynamic three-month window. They use a three-month look back and a three-month look ahead.

SPEAKER_01 5:53

Now the look back makes total sense to me. A doctor asks if you have engaged in certain behaviors in the last 90 days, but looking forward, anticipating behavior.

SPEAKER_00 6:02

Yeah, what's fascinating here is how proactive this is. A doctor will look for specific triggers in your recent past, or triggers you anticipate in your near future.

SPEAKER_01 6:11

Like what kind of triggers?

SPEAKER_00 6:12

Or we're talking about things like receptive condomless anal sex with casual partners, or having condomless sex with an untreated HIV-positive partner.

SPEAKER_01 6:21

Okay.

SPEAKER_00 6:21

Which notably includes serodiscordant couples who are planning natural conception. It also covers sharing injecting equipment or engaging in what the guidelines call chemsex, which is sexualized drug use.

SPEAKER_01 6:35

And the guidelines emphasize that it's not just behavioral triggers, right? There are biological indicators too.

SPEAKER_00 6:40

Yes. If a patient presents with a specific STI, specifically rectal gonorrhea, rectal chlamydia, or infectious syphilis, that is an immediate glaring indicator for pre-EP.

SPEAKER_01 6:53

Because it implies a certain network of exposure?

SPEAKER_00 6:55

Exactly. The presence of those specific infections strongly suggests the person is part of a sexual network and behavioral pattern where HIV exposure is a highly probable event, even if they don't explicitly recognize the risk themselves.

SPEAKER_01 7:08

But I want to push back on that look-ahead concept for a second.

SPEAKER_00 7:11

Sure. Treating something that has already happened or an infection you already have is standard medicine. But wait, so even just anticipating a lifestyle change is a legitimate medical indication to start taking a powerful daily anti-retroviral. Is like if I tell my doctor I'm leaving a long-term monogamous relationship next month or I'm planning a trip overseas to a high prevalence area, that alone gets me the prescription.

SPEAKER_01 7:36

It absolutely does. And this raises an important question about what modern medicine is actually treating. It's not just about stopping a physical virus anymore.

SPEAKER_00 7:44

What else is it treating?

SPEAKER_01 7:45

It's about proactive public health and mental well-being. The guidelines explicitly state that pre-AP should be offered if HIV anxiety is significantly affecting a person's quality of life.

SPEAKER_00 7:55

Oh wow. Treating the psychological burden of risk.

SPEAKER_01 7:58

Yeah. They're acknowledging that the fear of HIV can be debilitating. Handing the patient the shield empowers them and removes that psychological weight, which is a massive leap forward in holistic care. But knowing you need the shield, or even just wanting it, isn't enough. Because this is a serious medication, doctors are required to run through a very strict pre-flight checklist before they ever write that prescription.

SPEAKER_00 8:21

Definitely.

SPEAKER_01 8:24

And that checklist is completely non-negotiable. First and foremost is the 72-hour rule.

SPEAKER_00 8:29

Right. If a patient comes in and says they had a high-risk exposure, say 48 hours ago, pure EM is the wrong tool.

SPEAKER_01 8:37

Because it's too late for the bouncer, the virus might already be on the dance floor.

SPEAKER_00 8:41

Exactly. In that scenario, they need P post-exposure prophylaxis. You use PPE to aggressively chase down a potential infection that might already be starting.

SPEAKER_01 8:51

And then what?

SPEAKER_00 8:52

Only after that 28-day course is finished and the patient tests negative, do you transition them to PREP for future protection?

SPEAKER_01 8:59

Okay, so assuming there's no recent exposure within 72 hours, the next mandate on the checklist is testing. And the guidelines are incredibly specific here.

SPEAKER_00 9:08

Very specific.

SPEAKER_01 9:09

You can't just use one of those rapid prick-your finger point of care tests or like a take-home self-test.

SPEAKER_00 9:15

No, those are explicitly forbidden as the sole diagnostic tool for starting pre-P. A doctor must order a fourth generation antigen antibody venous blood test. They have to draw blood from a vein and send it to a lab.

SPEAKER_01 9:28

But why the strictness? I mean, why isn't the rapid test good enough if it's looking for HIV?

SPEAKER_00 9:33

Because rapid tests lack the sensitivity to detect acute HIV, which is the very earliest stage of the infection. A fourth generation test looks for both the body's antibodies and the actual virus's antigen.

SPEAKER_01 9:46

So they have to be absolutely sure.

SPEAKER_00 9:47

Yes. Before anyone starts pre-PP, the doctor must entirely exclude the possibility that the patient already has an active, acute HIV infection. They'll even conduct a clinical interview looking for physical symptoms of seroconversion.

SPEAKER_01 10:00

Like what?

SPEAKER_00 10:01

Things like fever, a rash, swollen lymph nodes, or even just a sore throat.

SPEAKER_01 10:05

So it's kind of like checking a car's engine before adding high octane fuel. If you add the specific fuel to a healthy engine, it runs perfectly and protects the car.

SPEAKER_00 10:12

Right.

SPEAKER_01 10:13

But what happens if there's already a tiny fire starting under the hood, which would be the acute HIV infection?

SPEAKER_00 10:18

That's where things get dangerous. If you introduce pre-EP during an acute infection, you'll actually force the virus to mutate.

SPEAKER_01 10:26

Oh, wow.

SPEAKER_00 10:27

Yeah. Taking just two NRTIs when you already have HIV isn't enough to fully suppress the virus, but it is enough evolutionary pressure to build a severe drug resistant strain.

SPEAKER_01 10:37

So you basically risk burning your best future treatment options.

SPEAKER_00 10:41

Exactly. That is why the negative blood test is mandatory. And the pharmaceutical benefits scheme, the PBS, requires that negative test to be no more than four weeks old.

SPEAKER_01 10:52

That makes the blood draw absolutely critical. What else is on the pre-flight checklist?

SPEAKER_00 10:56

The organ check. Specifically the kidneys. The doctor has to check the patient's EGFR, which is a measure of kidney function and how well they filter waste.

SPEAKER_01 11:05

And what's the threshold there?

SPEAKER_00 11:06

If a patient's EGFR is under 30, they are absolutely not suitable for pre-PP. The kidney simply cannot handle the drug clearance, and the medication will cause serious toxicity.

SPEAKER_01 11:15

And if the kidney function is borderline, say between 30 and 60.

SPEAKER_00 11:19

Then the standard TDFTC formulation is just too heavy for those kidneys. In that case, the doctor has to pivot to a different, less kidney toxic formulation called TAFTC tenophavera aliphenamide.

SPEAKER_01 11:33

Okay, that makes sense.

SPEAKER_00 11:34

And alongside the kidneys, doctors check hepatitis A, B, and C serology and run pregnancy tests for those with childbearing potential.

SPEAKER_01 11:42

Right.

SPEAKER_00 11:42

They also review the patient's other medications to ensure they aren't taking things that compound kidney damage, like high doses of NSIDs, your standard over-the-counter anti-inflammatories.

SPEAKER_01 11:53

It's a highly comprehensive workup. But what happens if during this workup that STI screen comes back positive? Say the patient has rectal chlamydia, which you mentioned earlier, is a trigger for needing pre-EP.

SPEAKER_00 12:04

Yeah.

SPEAKER_01 12:04

Do they have to wait until the chlamydia is cured to get their shield?

SPEAKER_00 12:08

Actually, no. Having an active STI does not delay the start of pre-PP. The doctor will prescribe antibiotics to treat the STI, but they will start the pre-EP immediately.

SPEAKER_01 12:17

Because time is of the essence.

SPEAKER_00 12:19

Exactly. Time is of the essence when the behavioral network indicates high exposure risk. And what's vital to note is that any general practitioner or nurse practitioner can prescribe this.

SPEAKER_01 12:29

Oh, really?

SPEAKER_00 12:29

Yeah, it operates on a PBS streamlined authority. You don't need to sit on a waiting list for a specialized infectious disease clinic.

SPEAKER_01 12:36

Okay, so the patient passes the pre-flight checklist. The blood test is negative, the kidneys are humming along, the doctor hands over the script. Now we get to the actual execution.

SPEAKER_00 12:46

The daily routine.

SPEAKER_01 12:47

Right, and this is where the source material outlines two completely different tactical approaches to taking this medication, driven entirely by biology. One is a daily routine, and the other is what I'm calling a tactical strike. Let's look at the daily routine first. Sure.

SPEAKER_00 13:02

Daily pre DP is exactly what it sounds like. You take one tablet every day at roughly the same time. But remember that biological quirk we mentioned earlier regarding absorption rates.

SPEAKER_01 13:12

The rectal versus vaginal tissue absorption.

SPEAKER_00 13:15

Yes. Because of how the drug builds up in different tissues, you can't just swallow one pill and go out that night expecting full protection. You have to start taking it seven days before an anticipated exposure to reach protective intracellular levels.

SPEAKER_01 13:29

A full seven days of lead time. And the guidelines note that for the daily method to be effective, you need to maintain a strict minimum once you start.

SPEAKER_00 13:38

Adherence is everything. You need at least four tablets a week to maintain efficacy. And if you forget a day, you just take your next scheduled dose. You never double up to compensate for a missed pill.

SPEAKER_01 13:48

And for a significant portion of the population, this daily routine is the only approved way to use puri. Like the guidelines are unwavering on this. Very strict. Daily dosing is the only option for cisgender women, for trans women on estrogen, for anyone having vaginal or frontal sex, and for people who inject drugs.

SPEAKER_00 14:05

That's right.

SPEAKER_01 14:06

But here's where it gets really interesting. Because if you don't fall into those specific categories, there is another way.

SPEAKER_00 14:13

Yes. It's called on-demand PEP, or the 211 method. It is technically an off-label use of the drug, meaning it's not officially approved by the Therapeutic Goods Administration for this specific dosing schedule.

SPEAKER_01 14:28

But doctors still prescribe it.

SPEAKER_00 14:30

Yeah, because it is fully endorsed by ASHM and the World Health Organization for Eligible Populations.

SPEAKER_01 14:36

Okay, let's break down the math of 211 because I am trying to imagine looking at my calendar and doing this reverse math in my head before a date. It requires serious strategic planning.

SPEAKER_00 14:46

It really does. So the math is highly specific. The two stands for the loading dose. You take two pills together between two and twenty four hours before you anticipate having sex. Okay. Then the first one is a single pill taken exactly 24 hours after that first loading dose. And the final one is another single pill taken 48 hours after the loading dase.

SPEAKER_01 15:05

Wait, so you're telling me I have to look at a clock, estimate when an encounter might happen, calculate backwards by at least two hours, take a double dose, and then set alarms for 24 and 48 hours later?

SPEAKER_00 15:15

Yeah, I mean that is the exact mental load required. But the payoff is that unlike the daily routine that takes seven days to build up, this 211 method provides instant protection from that very first double dose.

SPEAKER_01 15:28

But my question is, why is this highly strategic, math-heavy method so restricted? Like, why is it only allowed for people assigned male at birth who aren't taking ostradiol?

SPEAKER_00 15:39

It all comes back to that biological quirk from the beginning of our discussion.

SPEAKER_01 15:42

The absorption speed.

SPEAKER_00 15:43

Exactly. Rectal tissue absorbs the drug incredibly rapidly. So a double dose two hours prior is enough to flood the rectal mucosa with protective NRTIs. Oh wow. But vaginal or cervical tissue, or tissue influenced by oestrogen therapies, simply does not absorb the drug that fast. It requires the steady cumulative buildup of daily dosing over a week to reach a protective threshold.

SPEAKER_01 16:06

And what about for people who inject drugs?

SPEAKER_00 16:08

Right. For intravenous drug use, the exposure goes directly into the bloodstream. It bypasses the mucosal tissues entirely. That direct bloodstream exposure demands the constant, high systemic drug levels that are only provided by strict daily dosing.

SPEAKER_01 16:21

It makes complete sense when you look at the mechanics, but it really highlights how personalized this medicine has to be. If you use the two-on-one method, it's great because you take fewer pills overall.

SPEAKER_00 16:32

Which means less cumulative drug exposure for your kidneys to process.

SPEAKER_01 16:36

Right. But the margin for error is razor thin. You have to be able to plan at least two hours ahead.

SPEAKER_00 16:42

It requires a patient who has infrequent sex, where the encounters are predictable enough to allow for that two-hour loading window.

SPEAKER_01 16:50

And if they aren't predictable.

SPEAKER_00 16:51

If a patient's risk becomes frequent or unpredictable, the guidelines advise the doctor to switch them to the daily routine immediately to avoid a lapse in the shield.

SPEAKER_01 17:02

So whether you are relying on the daily habit or doing the tactical 211 math, being on pre-EP requires active ongoing maintenance. This is not a set it and forget it intervention.

SPEAKER_00 17:12

No, it definitely not.

SPEAKER_01 17:13

You don't just get the pills and disappear into the sunset.

SPEAKER_00 17:16

The clinical oversight is continuous. Quarterly reviews are mandatory. Every 90 days, the patient must return for a repeat HIV test and a full STI screen.

SPEAKER_01 17:25

Even if they aren't taking it daily.

SPEAKER_00 17:27

Yes. The guidelines stress that this applies, even if they are using the on-demand method and only having sex once every few months, the monitoring does not stop.

SPEAKER_01 17:36

And there are side effects to monitor as well, right? That the sources mention something called startup syndrome.

SPEAKER_00 17:41

Yeah, in the first month, a subset of patients experience headaches, nausea, or flatulence. It usually settles down quickly as the body acclimates to the NRTIs.

SPEAKER_01 17:51

Okay, good.

SPEAKER_00 17:51

But the long-term monitoring is focused on deeper physiological changes. Doctors are continually running blood work to check for creeping kidney toxicity and monitoring for any reduction in bone mineral density.

SPEAKER_01 18:04

So what happens when you want to land the plane? You've been on pre P for a year, your lifestyle changes, maybe you enter a monogamous relationship, the risk goes away, and you want to stop. Right. You can't just quit cold turkey the morning after your last encounter, can you?

SPEAKER_00 18:18

No, you can't. The landing is just as mathematically precise as the takeoff. The stopping rules depend entirely on your biology and your dosing methods. If you are assigned male at birth and not on estrogen, whether you're taking it daily or on demand, you must continue taking the pills until 48 hours have passed since your last exposure.

SPEAKER_01 18:37

Just two days of coverage after the event clears you?

SPEAKER_00 18:41

Correct. But for everyone else, cisgender women, trans women on estrogen, people having vaginal sex, or injecting drug users, the rule is drastically different.

SPEAKER_01 18:52

What is it?

SPEAKER_00 18:53

They must continue taking daily PPP for a full 28 days after their last exposure.

SPEAKER_01 18:58

28 days? That is a massive difference in strategy. Again, entirely driven by how long the specific tissue takes to clear the virus and secure the shield.

SPEAKER_00 19:07

Yes. And stopping isn't always a simple conversation with the GP. Sometimes landing the plane requires calling in air traffic control. The guidelines specify that complex cases require immediate specialist referral.

SPEAKER_01 19:18

Like what kind of cases?

SPEAKER_00 19:20

For instance, if a patient has chronic hepatitis B.

SPEAKER_01 19:22

Because the pre-P medication also suppresses the HEP B virus.

SPEAKER_00 19:25

Exactly. The NRTIs are dual-acting. If you just stop taking pre-PP abruptly without a transition plan, the hepatitis B virus can rebound aggressively.

SPEAKER_01 19:33

Oh, that sounds bad.

SPEAKER_00 19:34

It is. This can cause a massive, potentially life-threatening inflammatory flare in the liver. So that requires careful specialist management. Specialists are also called in if kidney function starts dropping significantly during those quarterly reviews, or obviously if an HIV test ever comes back, positive or indeterminate.

SPEAKER_01 19:54

Wow. So what does this all mean for you, the listener? Whether you work in healthcare, whether you're considering pre-EP yourself, or you're just fascinated by the evolution of public health, we've covered a lot of ground today.

SPEAKER_00 20:06

We really have.

SPEAKER_01 20:06

We've seen how two simple NRTIs act as bounsters to block reverse transcription. We've seen how doctors use three-month lookbacks and look aheads to treat the anxiety of risk, not just the behavior itself.

SPEAKER_00 20:18

Which is such a vital shift.

SPEAKER_01 20:20

And we've explored the wild biological differences between needing a seven-day daily runway versus calculating a two-hour tactical loading dose. It shows an incredible level of trust placed in the patient's hands.

SPEAKER_00 20:32

It is a remarkable shift in patient empowerment, but you know, it's vital to remember the clinical context of that trust. Right. Pre-EP is a highly effective shield against HIV. But it is an incredibly specific, narrow shield. It does absolutely nothing to prevent other STIs like syphilis or gonorrhea, and it offers no contraceptive protection.

SPEAKER_01 20:54

That is a great point.

SPEAKER_00 20:56

That is why the guidelines constantly reinforce that comprehensive sexual health remains a multi-tool approach.

SPEAKER_01 21:02

It's just one piece of the puzzle, albeit a revolutionary one. But I want to leave you with a thought. As we were reading through the depths of these clinical guidelines, there was a tiny detail buried near the end. Almost a footnote about the future of this medication.

SPEAKER_00 21:15

Ah, yes. The inclusion of long-acting injectable pre-PP cabotag.

SPEAKER_01 21:20

Exactly. Right now we are relying on strict daily pill routines. We're relying on patients to remember to take a pill seven days in advance or to sit down and calculate a 2-1-1 dosing schedule in the heat of the moment.

SPEAKER_00 21:32

That's a lot to manage.

SPEAKER_01 21:33

It requires a lot of math and a lot of memory. But if the future of this shield is a single injection that lasts for months at a time, how completely will human behavior and public health change?

SPEAKER_00 21:44

It's gonna be fascinating to watch.

SPEAKER_01 21:46

The science isn't stopping here. The biological shield is only going to get stronger, and the future of prevention might soon make all this pill timing math a thing of the past. Think about what a world looks like when the shield is just automatic.